Triglimibrit 1mg/500mg/0.3mg Tablet SR
Marketer
Elbrit Life Sciences
Salt Composition
Glimepiride (1mg) + Metformin (500mg) + Voglibose (0.3mg)
Overview Triglimibrit 1mg/500mg/0.3mg Tablet SR
Diabetax Trio 1mg/500mg/0.3mg Extended-Release Tablets are classified as antidiabetic medications. This combination therapy is indicated for managing type 2 diabetes in adults, effectively regulating blood glucose levels. Diabetax Trio should be ingested with food, consistently at the same time daily for optimal results. Dosage is determined by your physician and may be adjusted based on your glycemic control. Continued use is crucial, even with well-managed blood sugar, as abrupt cessation can lead to hyperglycemia, increasing the risk of kidney complications, vision impairment, neuropathy, and limb loss. This medication forms part of a comprehensive diabetes management plan, incorporating diet, exercise, and weight management as recommended by your doctor. Lifestyle modifications significantly impact diabetes control. Hypoglycemia (low blood sugar) is the most prevalent adverse effect of Diabetax Trio. Learn to recognize its symptoms—sweating, dizziness, headache, tremors—and appropriate countermeasures. Maintaining regular mealtimes and carrying a readily available fast-acting glucose source (e.g., sugary snacks, fruit juice) is essential for prevention. Alcohol consumption elevates hypoglycemia risk and should be avoided. Other potential side effects include altered taste perception, nausea, diarrhea, abdominal discomfort, cephalgia, edema, visual disturbances, fractures, and upper respiratory infections. Weight gain may occur in some patients. This medication is contraindicated in individuals with type 1 diabetes, diabetic ketoacidosis, or severe hepatic or renal impairment. Prior heart conditions should be disclosed to your doctor before commencing treatment, as suitability may be affected. Pregnant or lactating women must consult their physician before use. Regular blood glucose monitoring is necessary, and your doctor may order blood tests to assess blood cell counts and liver function.
Primary Ingredients of Triglimibrit 1mg/500mg/0.3mg Tablet SR
No text provided to rephrase.
Uses of Triglimibrit 1mg/500mg/0.3mg Tablet SR
Managing type 2 diabetes
Major Benefits of Triglimibrit 1mg/500mg/0.3mg Tablet SR:
Consume this medication precisely as your physician directs, adhering to both the prescribed dosage and duration. Ingest the entire tablet without chewing, crushing, or fracturing it. Administer Triglimibrit 1mg/500mg/0.3mg Extended-Release Tablet on an empty stomach.
Common Side effects of Triglimibrit 1mg/500mg/0.3mg Tablet SR:
- Nausea
- Diarrhea
- Abdominal pain
- Hypoglycemia (low blood glucose level)
- Loss of appetite
How to use Triglimibrit 1mg/500mg/0.3mg Tablet SR:
Follow your doctor's instructions precisely regarding the dosage and treatment length for this medication. Ingest the Triglimibrit 1mg/500mg/0.3mg Tablet SR whole; do not chew, crush, or divide it. Administer this medication on an empty stomach.
How Triglimibrit 1mg/500mg/0.3mg Tablet SR works:
The extended-release Triglimibrit tablet (1mg/500mg/0.3mg) combines three antidiabetic agents.
SAFETY ADVICE
AlcoholUNSAFE
Concurrent use of alcohol and Triglimibrit 1mg/500mg/0.3mg SR tablets is inadvisable.
PregnancyCONSULT YOUR DOCTOR
Using Triglimibrit 1mg/500mg/0.3mg Extended-Release tablets during pregnancy might pose risks. While human data is scarce, animal research indicates potential harm to the fetus. A physician will assess the advantages against possible risks prior to prescribing. Seek medical advice.
Breast feedingCONSULT YOUR DOCTOR
Prolonged-release Triglimibrit tablets (1mg/500mg/0.3mg) are likely unsuitable for breastfeeding mothers. Preliminary human evidence indicates potential transfer to breast milk, posing a risk to the infant.
DrivingCAUTION
Driving may be impaired by excessively low or high blood sugar levels. Refrain from driving if such symptoms arise.
KidneyUNSAFE
The use of Triglimibrit 1mg/500mg/0.3mg SR tablets is likely unsafe for individuals with kidney impairment and should be omitted. Patients should seek medical advice. Furthermore, this medication is not advised for those with advanced kidney disease.
LiverCAUTION
Patients with liver disease should use Triglimibrit 1mg/500mg/0.3mg Tablet SR cautiously, potentially requiring dosage modification. A physician's consultation is advised. For those with mild to moderate liver impairment, Triglimibrit 1mg/500mg/0.3mg Tablet SR is typically initiated at a low dose; however, it's contraindicated in patients with severe liver disease.
What if you forget to take Triglimibrit 1mg/500mg/0.3mg Tablet SR :
Should you forget to take your Triglimibrit 1mg/500mg/0.3mg Tablet SR, administer it immediately upon remembering. Nevertheless, if your next scheduled dose is imminent, omit the missed dose and resume your usual dosing pattern. Avoid taking a double dose.
Facts to Know About Triglimibrit 1mg/500mg/0.3mg Tablet SR
| Label | Value |
|---|---|
| Developing Habits | No. |
| Treatment Category | Diabetes Management |
3,018 People bought this recently